These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 4063130)

  • 1. Influenza vaccine--the effect of virus strain and dosage on antibody response.
    Clarke TK; Harcus AW; Ward A; Moore RA
    Br J Clin Pract; 1985 Sep; 39(9):359-63. PubMed ID: 4063130
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of bacterial peptidoglycans on the immune response of hamsters to influenza virus vaccines.
    Crawford CR; Jennings R; Bradford N; Potter CW
    Clin Exp Immunol; 1982 Jun; 48(3):739-46. PubMed ID: 6811173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of HLA in immune response to influenza-A immunization.
    Cunningham-Rundles S; Brown A; Gross D; Braun D; Hansen JA; Good RA; Armstrong D; Dupont B
    Transplant Proc; 1979 Dec; 11(4):1849-52. PubMed ID: 394432
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.
    Hehme N; Engelmann H; Kuenzel W; Neumeier E; Saenger R
    Virus Res; 2004 Jul; 103(1-2):163-71. PubMed ID: 15163505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal DNA vaccine for influenza is immunogenic in humans.
    Drape RJ; Macklin MD; Barr LJ; Jones S; Haynes JR; Dean HJ
    Vaccine; 2006 May; 24(21):4475-81. PubMed ID: 16150518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristic of humoral response of elderly to inactivated influenza vaccine.
    Siennicka J
    Arch Immunol Ther Exp (Warsz); 1996; 44(5-6):389-94. PubMed ID: 9017157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
    Goji NA; Nolan C; Hill H; Wolff M; Noah DL; Williams TB; Rowe T; Treanor JJ
    J Infect Dis; 2008 Sep; 198(5):635-41. PubMed ID: 18694338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants.
    Keitel WA; Atmar RL; Nino D; Cate TR; Couch RB
    J Infect Dis; 2008 Oct; 198(7):1016-8. PubMed ID: 18729777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.
    Treanor J; Nolan C; O'Brien D; Burt D; Lowell G; Linden J; Fries L
    Vaccine; 2006 Jan; 24(3):254-62. PubMed ID: 16129526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.
    Del Giudice G; Hilbert AK; Bugarini R; Minutello A; Popova O; Toneatto D; Schoendorf I; Borkowski A; Rappuoli R; Podda A
    Vaccine; 2006 Apr; 24(16):3063-5. PubMed ID: 16464520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific antibody response after influenza immunization in systemic lupus erythematosus.
    Abu-Shakra M; Press J; Varsano N; Levy V; Mendelson E; Sukenik S; Buskila D
    J Rheumatol; 2002 Dec; 29(12):2555-7. PubMed ID: 12465151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
    Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC
    J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine.
    Kojimahara N; Maeda A; Kase T; Yamaguchi N
    Vaccine; 2006 Aug; 24(33-34):5966-9. PubMed ID: 16777274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E-rosette forming cells and humoral antibody titres in humans after vaccination with three different inactivated influenza virus vaccines A/USSR/92/77 (H1N1).
    Schmidt S; Süss J; Oehring H; Schmidt J
    Acta Virol; 1982 Dec; 26(6):466-73. PubMed ID: 6132540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased antibody response to influenza vaccine among nursing-home residents who received recalled vaccine--New York, 1996.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1996 Dec; 45(50):1100-2. PubMed ID: 8999309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the potency, optimal antigen level and lasting immunity of inactivated avian influenza vaccine prepared from H5N1 virus.
    Sasaki T; Isoda N; Soda K; Sakamoto R; Saijo K; Hagiwara J; Kokumai N; Ohgitani T; Imamura T; Sawata A; Lin Z; Sakoda Y; Kida H
    Jpn J Vet Res; 2009 Feb; 56(4):189-98. PubMed ID: 19358446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
    J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.
    Bungener L; Geeraedts F; Ter Veer W; Medema J; Wilschut J; Huckriede A
    Vaccine; 2008 May; 26(19):2350-9. PubMed ID: 18400340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of influenza vaccine formulation with a detailed analysis of the cytokine response.
    Szyszko E; Brokstad K; Cox RJ; Hovden AO; Madhun A; Haaheim LR
    Scand J Immunol; 2006 Nov; 64(5):467-75. PubMed ID: 17032238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.